A retrospective real world study assessing impact of mAbs on COVID-19-related outcomes among patients with lymphoid malignancies
Latest Information Update: 27 Jan 2023
At a glance
- Drugs Bamlanivimab (Primary) ; Bebtelovimab (Primary) ; Casirivimab/imdevimab (Primary) ; Cilgavimab/tixagevimab (Primary) ; Sotrovimab (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 27 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition